Continuous Glucose Monitoring Devices Market is estimated to be valued at USD 7.81 Bn in 2025 and is expected to reach USD 15.12 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.
The global continuous glucose monitoring devices market is experiencing strong growth due to the increasing demand for continuous glucose monitors (CGM) and rise in burden of diabetes around the world. Moreover, increasing adoption of technologically advanced devices and growing geriatric population across the globe is expected to propel growth of the market. However, factors such as high cost of continuous glucose monitors and poor reimbursement policies are expected to hamper growth of the global continuous glucose monitoring devices market.
|
Current Events |
Description and its impact |
|
Dexcom G7 15 ‑ Day CGM System FDA Clearance |
|
|
Abbott's FreeStyle Libre Rio OTC CGM System FDA Clearance |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The pipeline for continuous glucose monitoring (CGM) devices is strong and quickly changing, with established companies and start-ups all committing to innovation in an effort to address accuracy, usability, and cost. Top performers like Dexcom, Abbott, and Medtronic are innovating next-generation CGM systems with longer-lasting sensors, better data integration, and real-time alerts.
Dexcom is pushing its G7 platform forward with additional software upgrades to improve performance and smart device compatibility. Abbott, on the other hand, is developing an expanded FreeStyle Libre portfolio with increased wear time for sensors and compatibility with insulin delivery systems. Medtronic's Synergy CGM, a component of its future-generation MiniMed platform, is designed to provide easy insertion and minimal calibration requirements.
Startups and new entrants are entering the pipeline as well, creating implantable and non-invasive CGM products, including needle-free sensors and optical-based glucose meters. Senseonics, for instance, is constructing the Eversense XL system with a six-month wear duration, which can help enhance patient compliance and lower costs in the long run.
Regulatory channels are also being optimized, with breakthrough designations and FDA approved for continuous glucose monitoring devices. Collaboration between digital health firms and developers of CGM is driving the pipeline even further, enabling individualized diabetes care through AI-powered analytics.
Overall, the CGM market pipeline is geared toward delivering more patient-friendly, cost-effective, and data-rich solutions. This innovation is vital to overcoming existing barriers such as affordability and reimbursement challenges, thereby expanding access and driving future market growth.
The patent environment of continuous glucose monitoring (CGM) devices is dynamic and growing, representing furious competition and innovation among major players. The large players such as Dexcom, Abbott, Medtronic, and Senseonics are among the leaders in holding numerous patents related to sensor technologies, data analytics, wireless transmission, biocompatible materials, and integration of devices with insulin pumps and smartphones.
Dexcom has acquired multiple patents for real-time glucose monitoring, sensor calibration methods, and miniaturization of devices. Abbott's patent collection revolves around its FreeStyle Libre technology, specifically in factory calibration, long sensor life, and flash glucose monitoring areas. Medtronic possesses patents for closed-loop systems, predictive warning, and multi-sensor platforms, which further establish its position both in CGM and automated insulin delivery.
Some of the trends emerging in the patent domain are non-invasive monitoring methods (for example, optical and transdermal sensing), convergence with artificial intelligence, and long-term implantable sensors. Intellectual property is also being sought in cloud computing for data management and connectivity with digital health platforms, indicative of how diabetes care is converging with digital health.
The geographical pattern of the patents is dominated by the United States, followed by the EU, Japan, and China, reflecting the intense emphasis on the protection of rights in key diabetes markets. Global protection is facilitated by many filings through the Patent Cooperation Treaty (PCT) route.
In short, the patent landscape for CGM is very busy, with ongoing innovation focused on enhancing sensor accuracy, wearability, and convenience for consumers. This activity within IP acts as both an obstacle for new entrants and a major competitive edge for incumbent players.
One of the key factors expected to augment the growth of the global continuous glucose monitoring devices market over the forecast period is the increasing demand for continuous glucose monitors (CGM) across the globe.
For instance, in early 2024, Medtronic expanded its Guardian Connect continuous glucose monitoring system availability in the United Kingdom, targeting both Type 1 and insulin-treated Type 2 diabetes patients. The Guardian Connect CGM offers real-time glucose monitoring with predictive alerts via a mobile app to help users manage glucose levels proactively.
Another factor which is augment the growth of the global continuous glucose monitoring devices market is the increasing prevalence of diabetes around the world. Diabetes is a chronic, and largely preventable, disease that can lead to cardiovascular disease, kidney failure, blindness, loss of limb, and loss of life.
According to the International Diabetes Federation (IDF), about 537 billion people (aged 20 to 79 year) worldwide are living with diabetes, and the number is expected to reach over 643 billion by 2030 and over 783 billion by 2045. This in turn is expected to increase the adoption of continuous glucose monitoring devices worldwide.
Increasing adoption of technologically advanced devices is expected to provide significant growth opportunities for players in the global continuous glucose monitoring devices market. For instance, CGMs are revolutionizing diabetes treatment with the introduction of technology such as Artificial intelligence (AI) in the healthcare industry.
In May 2023, January AI launched a new generative AI-enabled app to estimate and predict the glucose response of individuals to more than 32 billion food items. The tool requires users to wear a continuous glucose monitor (CGM) only once and it can function even if members are not using a CGM.
Growing geriatric population across the globe is expected to offer significant growth opportunities for players in the global continuous glucose monitoring devices market. For instance, according to the WHO, the world's population of people aged 60 years and older will double (2.1 billion) by 2050.
Diabetes is common in older adults, affecting an estimated 33% of people aged 65 and older. The geriatric population is more at risk of developing diabetes-related complications than younger once. The potential benefits of CGM in older adults are widespread; reduce hyper-glycaemia and hypo-glycaemia, improve quality of life, and prevent diabetes-related complications.
Growing awareness among people about the benefits of CGM device, such as minimally invasive, speedy and accurate results, and pain free, among others. This in turn leads to increasing demand for these devices. According to the American Diabetes Association, around 133 billion Americans live with diabetes or prediabetes. More than 10 billion Americans (or 31%) are treated with insulin and stand to benefit from a continuous glucose monitor. This trend is expected to continue during the forecast period, driving the market growth.
Digital diabetes management devices, like smart insulin pens, smart insulin pumps, smart glucose meter, and continuous blood glucose monitoring devices, help people with diabetes (type I and II) to both monitor and manage their blood glucose levels.
Thus, with the rise in burden of diabetes, increasing awareness among people, and introduction of technologically advanced CGM devices, the adoption of such devices is also increasing rapidly. This trend is also expected to continue over the forecast period, driving the market growth.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Out of which, Sensors Segment is expected to dominate the continuous glucose monitoring devices market over the forecast period and this is attributed to the increasing demand for CGMs. Sensors are the most important part of CGM devices. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar (glucose) levels. Receivers Segment is also expected to witness significant growth in the near future and this is owing to the increasing adoption of digital diabetes care devices.
Based on End User, the market is segmented into Hospitals, Home Care, and Others. Out of which, Hospitals Segment is expected to dominate the market during the forecast period and this is attributed to the rise in burden of diabetes across the globe. Home Care Segment is also expected to witness significant growth in the near future and this is owing to increasing adoption of portable diabetes care devices.
To learn more about this report, Download Free Sample
North America is expected to gain highest share in the market during the forecast period owing to the increasing cases of diabetes, growing geriatric population, increasing demand for continuous glucose monitoring devices, and increasing adoption of alternate and novel devices in the region.
For instance, in February 2025, the Food and Drug Administration (FDA) approved Senseonics’ new continuous glucose monitor (CGM), called the Eversense E3 System, for diabetes with a sensor that can last for up to 6 months. According to the company, the device is the longest lasting CGM approved in the United States and the world.
Asia Pacific is also expected to witness robust growth in the global continuous glucose monitoring devices market owing to the increasing prevalence of diabetes, growing geriatric population, high demand for continuous glucose monitoring devices, and increasing awareness among people in the region. For instance, according to the World Health Organization (WHO), in India, more than 77 billion people above the age of 18 years are suffering from diabetes (type 2) and nearly 25 billion are prediabetes (at a higher risk of developing diabetes in near future). While. 50% are unaware of their diabetic status which leads to health complications if not detected and treated early.
The U.S. is the largest market for CGM devices, promoted by a high prevalence of diabetes, well-developed healthcare infrastructure, and favorable reimbursement policies for Type 1 diabetes. Business centers such as Dexcom and Medtronic are located there, and FDA approvals drive high-speed innovation and adoption.
Germany dominates the European market for CGM because of its extensive healthcare coverage and early adoption of health technologies. Reimbursement for Type 1 and certain Type 2 diabetics has enhanced access, promoting market growth and greater competition among providers.
China is becoming a significant market for CGM because of its huge diabetic population and expanding middle class. Government programs to increase healthcare access and increasing awareness regarding the management of diabetes are drawing local as well as international CGM manufacturers.
Japan's aging population and diabetes incidence have fueled increasing demand for CGM devices. Japan also has a highly advanced consumer base and a policy drive to digitize healthcare, making the nation a flagship market in Asia-Pacific.
The UK is a dominant force in Europe's CGM market, helped along by NHS reimbursement for CGMs for qualifying patients. Government subsidies and national diabetes initiatives have helped drive the take-up of CGMs, especially by Type 1 diabetics.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 7.81 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.9% | 2032 Value Projection: | USD 15.12 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic, Dexcom, Inc., Abbott, Novo Nordisk A/S, Ypsomed, GlySens Incorporated, and F. Hoffmann-La Roche Ltd., among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Continuous glucose monitor (CGM) is a medical device used by people with diabetes to monitor blood sugar (glucose) on a continual basis, e.g. people with type I, type II diabetes, or other types of diabetes (e.g. gestational diabetes).
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
